Blood thinners after heart attack with widened arteries

This trial tests a blood thinner, rivaroxaban, to see if it can prevent blood clots from forming in the heart after a specific type of heart attack (STEMI) that affects the front part of the heart.

This study tests whether taking dabigatran (a blood thinner) combined with ticagrelor (a blood clot preventer) is safe and effective for patients with irregular heart rhythm (atrial fibrillation) who recently had a heart attack and received a stent. The goal is to prevent future blood clots while minimizing bleeding risks.

This trial studies how to treat people who recently had acute coronary symptoms (like a heart attack or unstable angina) and who also have enlarged or swollen coronary artery segments (coronary ectasia or true aneurysm). It may help by testing a specific approach for reducing risks related to these abnormal artery changes.

This trial is testing whether a newer type of blood thinner (called a NOAC) can be used safely right after a heart attack or related event, in addition to the standard two antiplatelet medicines. It focuses on patients who have higher risk signs, like elevated D-dimer levels or a higher PARIS risk score, to see if this approach is safe and effective at preventing future heart problems.

This trial compares two blood-thinning medicines (bivalirudin vs. heparin) given during angioplasty to people who've already had a clot-buster for a heart attack. The goal is to see which one works better to keep arteries open without increasing bleeding risk.

This trial tests a new approach to treating blood clots during a heart attack to prevent damage to the small blood vessels in your heart. You would receive this treatment during an emergency catheterization procedure if you have signs of a major heart attack.